Background. Previous studies have shown that the durability of serological response is impaired in successfully vaccinated human immunodeficiency virus-1 (HIV-1) positive subjects after receiving 2 doses of inactivated hepatitis A virus (HAV) vaccine. We evaluated whether 3 doses compared with 2 doses of HAV vaccine could improve the long-term seroprotection for this susceptible group.
Hepatitis A virus (HAV) infection is the most common form of acute viral hepatitis worldwide [1] . Approximately 1.4 million clinical cases and tens of millions of HAV infections occur every year, although these figures are likely to underestimate the high proportion of asymptomatic cases [1] . The case fatality rate is low, however, ranging from 0.1% in children aged <15 years to 2.1% in adults aged >40 years [1, 2] . Improved sanitation in many parts of the world, including Taiwan, has resulted in a greater proportion of the population remaining susceptible to the disease, which is more severe in adulthood [2] [3] [4] [5] [6] .
Among persons living with human immunodeficiency virus (HIV), men who have sex with men (MSM) are more susceptible to HAV infection. Among such individuals, HAV infection is approximately 1.5-3 times more prevalent than among the general population [7, 8] and causes more episodes of severe disease, partly due to the higher burden of chronic liver disease [9] [10] [11] . Moreover, HIV-positive individuals have higher peak HAV loads and prolonged duration of viremia, with important public health consequences for transmission within the community [12] . Although routine vaccination of HIV-positive adults is not widely accepted, the World Health Organization, the US Advisory Committee on Immunization Practices guidelines, the British HIV Association (BHIVA) guidelines for the immunization of HIV-positive adults, and the European AIDS Clinical Society all recommend vaccinating HIV-positive persons if other risk-conferring lifestyle or medical conditions concur [13] [14] [15] [16] . Men who have sex with men and injection drug users are considered at higher risks of acquiring HAV [8, 17, 18] . For these at-risk HIV-positive persons, the most widely recommended vaccination schedule is 2 doses of formaldehyde-inactivated vaccine separated by 6-12 months [1] .
Compared with healthy controls, the immune response to the HAV vaccine is impaired in HIV-positive patients, with seroconversion rates after 2 doses of vaccine ranging 48.5%-93.9% [1] . Moreover, the duration of protection is impaired in successfully vaccinated HIV-positive patients [19] such that the BHIVA recommends a booster vaccine dose every 5 years [16, 20] . However, few studies have assessed the duration of protection provided by HAV vaccination in HIV-positive adults, and none have assessed the duration of protection provided by >2 doses of HAV vaccination beyond the 4th year [20, 21] . Although previously Launay et al and our group have demonstrated that addition of a 3rd dose can augment both the proportion of primary responders and the absolute concentrations of HAV antibodies shortly after vaccination, the aim of this study was to determine whether the dose-response persists in the long-term with implications on how many doses to be delivered in the primary series and the timing of booster doses for this vulnerable population [22, 23] .
METHODS

Study Population and Settings
This prospective cohort study of HIV-positive males aged 18-40 years who were HAV vaccine-naive and seronegative for anti-HAV immunoglobulin G (IgG) at baseline was conducted at the National Taiwan University Hospital. Subjects were vaccinated with 2 or 3 doses of HAV vaccine (HAVRIX 1440) between June 2009 and December 2010 according to a 0-6-month schedule (2 doses) or 0-1-6-month schedule (3 doses) as previously described [23] . All participants were then followed for 5 years, and serum samples were obtained biannually at months 12, 18, 24, 30, 36, 42, 48, 54 , and 60 for determination of anti-HAV antibody titers.
Before and throughout the study period, participants had free access to regular outpatient HIV care including combination antiretroviral therapy (cART) and monitoring of CD4 cell count and plasma HIV RNA load as part of the public health program of Taiwan Centers for Disease Control for HIV infection and AIDS. cART was defined as the use of at least 3 agents from at least 2 classes of antiretroviral agents according to the local treatment guidelines. The study was approved by the Research Ethics Committee of the hospital, and the participants gave written informed consent (registration no. 200903063M).
Laboratory Methods
The anti-HAV antibody titers were determined with the use of a commercially available enzyme-linked immunosorbent assay method (ETI-AB-HAVK PLUS; DiaSorin, Saluggia, Italy) [23] . The laboratory staff was unaware of the doses of HAV vaccine the subjects had received. Plasma HIV RNA load was quantified using the Cobas Amplicor HIV-1 Monitor test with a lower detection limit of 20 copies/mL, and CD4 count was determined using FACFlow (BD FACS Calibur, Becton Dickinson, CA). The CD4 counts and plasma HIV RNA load were monitored 1 month after initiation of cART in antiretroviral-naive participants or after a change of regimens for virological failure and every 3-6 months thereafter.
Definitions
Seroconversion was defined by anti-HAV antibody concentrations of ≥20 mIU/mL. Participants were classified as primary responders if they had documented seroconversion at month 12 (ie, 6 months after the last vaccine dose and before month 18). Those lacking seroconversion at month 12 and before month 18 were classified as primary nonresponders. Primary responders were followed for the persistence of antibody responses for the next 4 years at 6-month intervals and were considered to have lost seroprotection (be seroreverters) if their anti-HAV IgG levels dropped to <20 mIU/mL during follow-up and remained <20 mIU/mL. Vaccinees with a one-off IgG level <20 mIU/mL that recovered to ≥20 mIU/mL at the next testing without meeting the definition of a natural booster event were considered technical blips and not seroreverters. In the per-protocol analysis of the persistence of the antibody responses to vaccination, vaccinees with missing serological data were excluded. In the intention-to-treat analysis, vaccinees with missing serological data were considered as seroreverters.
Natural booster events among primary responders by exposure to circulating HAV were defined by any sustained secondary rises of ≥2-fold magnitude above the preceding anti-HAV IgG titers after an initial decline in IgG titers that was otherwise unexplained by additional booster dose(s) of HAV vaccines. A crude incidence rate of HAV acquisition was calculated from the number of natural booster events.
Late seroconversion occurring after month 18 among the primary nonresponders were classified as (1) late effects of vaccination and immune restoration when subthreshold titers increase gradually from 1-19 to ≥20 mIU/mL and were sustained for at least 6 months or as (2) responses following natural HAV infection if anti-HAV IgG increased suddenly from below the level of detection (ie, 0 mIU/mL) to ≥2-fold the threshold value of protection (ie, >40 mIU/mL) at any point during follow-up and was sustained for at least 6 months in the absence of additional vaccination(s).
Statistical Analysis
The analyses were conducted using the statistical package SAS 9.2. Chi-square tests or, if necessary, Fisher's exact tests were used for categorical variables. Student's t and Mann-Whitney U tests were used for numerical variables. Because observations were made over time periods, generalized estimating equations to account for the interdependence among observations were used to compare mean response rates to different HAV vaccine doses, with adjustments made for time-updated variables, including the patient's age at time of vaccination and at each testing, the CD4 cell counts >350 cells/µL at baseline and CD4 gains at each testing (in increments of 50 cells/µL), suppressed plasma HIV RNA load to <20 copies/mL at baseline and each testing, receipt of cART at time of vaccination and at each testing, baseline hepatitis B coinfection defined by the presence of hepatitis B surface antigen at time of vaccination, hepatitis C virus (HCV) infection defined by the seroconversion of anti-HCV antibody, or syphilis defined as an acute 4-fold increase in rapid plasma reagin titers combined with clinical findings compatible with early syphilis (primary, secondary, or early latent syphilis) or confirmed by the Treponema pallidum hemagglutination assay during the study period. A stepwise model comparison and selection were used to determine the final model. We used the SAS PROC GENMOD procedure to fit generalized estimating equation models. Odds ratios (ORs) for each prognostic factor and 95% confidence intervals (CIs) were also calculated. All statistical tests were 2-tailed, and P values <.05 were considered significant.
RESULTS
The study cohort comprised 365 HIV-positive MSM with a mean age of 30 (standard deviation [SD] = 5.2) years and CD4 count of 485 (SD = 215) cells/µL. Of 365 vaccinees, 334 had their anti-HAV titers determined at month 12 and could be classified as primary responders or nonresponders. There were 110 (87.3%) primary responders and 16 (12.7%) nonresponders among the 126 vaccinees who received 2 doses of HAV vaccine, and 185 (88.9%) primary responders and 23 (11.1%) nonresponders among the 208 vaccinees who received 3 doses and were followed beyond month 12 ( Figure 1 ). The clinical characteristics of the overall cohort and these 4 subgroups are shown in Table 1 .
At baseline, there were significant differences between the 2-dose and 3-dose primary responders, with the former having higher baseline CD4 counts (560 vs 470 cells/µL), lower plasma HIV RNA load (2.5 vs 2.9 log 10 copies/mL), and higher cART coverage (70.0% vs 58.9%). With regards to viral hepatitis and syphilis coinfections, the proportions of patients with chronic viral hepatitis were comparable between the 2 groups, although prior syphilis was more frequent among the 2-dose versus the 3-dose responders (24.7% vs 14.2%; P = .03). Despite these differences, the crude primary response rates of the 3-dose group with more advanced HIV disease were noninferior to the 2-dose group (88.9% vs 87.3%; P = .65). After matching baseline immunologic and virologic characteristics, the primary response of the 3-dose group by per-protocol analysis was in fact higher than the 2-dose group (91.7% vs 81.6%; P = .04; data not shown because it was previously reported in our earlier study [23] ).
Within dosing groups, there were marked differences in the surrogate markers of baseline immune status between primary responders and nonresponders, particularly for the 3-dose group, with nonresponders having, as expected, lower mean CD4 counts than responders (415 vs 560 cells/µL, P = .02 for the 2-dose group; 315 vs 470 cells/µL, P = .001 for the 3-dose group). There were also significantly fewer subjects with undetectable plasma HIV RNA load at the time of vaccination among those who did not seroconvert compared with those who seroconverted after 3 doses of vaccination (21.7% vs 43.8%; P = .046).
At the end of the 5-year study, the overall mean CD4 counts and the proportions of viral suppression and subjects taking cART had increased from 485 (SD = 215) at baseline to 635 (SD = 252) cells/µL, from 44.1% to 80.2%, and from 61.6% to 91.2%, respectively. Because of universal access to HIV care, there were no longer any significant differences in the CD4 counts, plasma HIV RNA load, and treatment status between the subgroups at the end of the 5 years of follow-up.
Persistence of Serological Responses Among Primary Responders
The percentages of persistent responders classified by anti-HAV IgG titers of ≥20 mIU/mL by intention-to-treat and per-protocol analyses in the following years are shown in Figure 2 (and the Supplementary Table) . The proportion of vaccinees with persistent seroprotection waned over time from 87.0% and 90.0% at 18 months to 76.4% and 78.9% after 60 months for the 2-dose and 3-dose groups, respectively, by intentionto-treat and from 93.4% and 94.7% at 18 months to 88.4% and 94.2% after 60 months for the 2-dose and 3-dose groups, respectively, by per-protocol analysis. However, persistent seroprotection was more consistently observed for the 3-dose vaccinees compared with the 2-dose vaccinees, although the difference between the 2 groups was only statistically significant in the per-protocol analysis in the 2nd-4th years after vaccination. The Kaplan-Meier curves also show a nonsignificant trend toward better maintained levels of seroprotection for the 3-dose versus 2-dose group (Figure 3) , whereas the geometric mean concentrations of specific anti-HAV IgG were consistently maintained at a higher level for the 3-dose group compared with the 2-dose group throughout the 5 years of follow-up (Figure 4) . 
Multivariable Analysis for Factors Associated With Persistent
Seroprotection
Because of the differences in surrogate markers of immune status and risk behavior between the 2 dosing groups at baseline, a multivariable analysis was conducted to identify the factors associated with persistent seroprotection, as shown in Table 2 . One additional dose of HAV vaccine in this study was associated with long-term persistence of seroprotection (adjusted OR [aOR] = 3.36; 95% CI = 1.14-9.93; P = .03), as was acquisition of syphilis during the follow-up period (aOR = 3.73; 95% CI = 1.00-13.9; P = .05). In contrast, acute HCV seroconversion during the follow-up was associated with loss of seroprotective responses (aOR = 0.08; 95% CI = .01-.48; P = .01).
Natural Boosters Among Primary Responders
Only 45.1% (133/295) of the primary responders had anti-HAV IgG concentrations that peaked at 12 months after vaccination and decayed gradually in a stepwise manner from the start of the study to the end of the follow-up period. The remainder (54.9%; 162/295) had either late peaking of anti-HAV IgG concentrations or sustained secondary rises of anti-HAV IgG after an initial decline during the following 4 years. When the secondary rises were of ≥2-fold magnitude above the previous anti-HAV IgG and sustained for 6 months, these were classified as natural booster events from exposure to circulating wild-type HAV. According to this definition, the overall crude incidence rate of HAV exposure among the primary responders was 19.6 per 1000 person-years of follow-up (PYFU), with a slightly higher incidence rate among 2-dose versus 3-dose vaccinees (21.9 vs 18.2 per 1000 PYFU). These episodes were asymptomatic, and only 3 were associated with modest elevations of either total serum bilirubin (to 3.76 mg/dL) or hepatic transaminases (within 3 times the upper limit of normal).
Late Seroconversion of Primary Nonresponders
Of the 16 nonresponders after 2 doses of HAV vaccination, 6 (37.5%) subsequently seroconverted, whereas of the 23 nonresponders after 3 doses of HAV vaccination, 11 (47.8%) subsequently seroconverted. Of these late seroconverters, the majority were classified as late effects of vaccination (5 in the 2-dose group and 9 in the 3-dose group). Only 1 late seroconversion in the 2-dose group and 2 seroconversions in the 3-dose group were classified as possibly due to asymptomatic HAV acquisition.
DISCUSSION
In this prospective long-term study of the durability of seroprotection conferred by vaccination with 2 or 3 doses of inactivated HAV vaccine (HAVRIX 1440) among HIV-positive MSM, we documented that anti-HAV IgG titers ≥20 mIU/mL were maintained by 88.4% and 94.2% of primary responders in the 2-and 3-dose groups, respectively. The 3-dose schedule appeared to achieve the durability of immune responses generated by a 2-dose schedule in healthy individuals, in whom protective antibody levels have been shown to persist beyond 10 years and underlying immune memory has been shown to provide protection far beyond the duration of anti-HAV antibodies [24] . Our findings suggest that, given immune reconstitution with cART and a primary 3-dose vaccine series, booster vaccinations after 5 years as recommended by the BHIVA may not be necessary in HIV-positive individuals in the same way that boosters are not recommended in healthy individuals. In addition, we confirm that the geometric mean concentrations of anti-HAV IgG were higher following 3 doses rather than 2 doses of HAV vaccination, rendering these titers more robust to rapid decline to subthreshold levels, despite the baseline lower CD4 counts, higher plasma HIV RNA load, and lower cART coverage of the 3-dose group. Furthermore, more late seroconversions, possibly as a delayed effect of cART, were observed among the primary nonresponders following 3 doses rather than 2 doses of vaccination (47.8% vs 37.5%). The multivariable analysis confirmed that the addition of a vaccine dose sandwiched at week 4 between the 0-and 6-month doses was an independent predictor of durable protection after 5 years (aOR = 3.36; P = .03). This dose-response sustainability has also been observed following vaccination with 7-valent pneumococcal conjugate vaccine and recombinant hepatitis B vaccine in HIV-positive persons receiving cART [25, 26] .
The multivariable analysis also identified recent episodes of syphilis during the follow-up period to be associated with persistent responses (aOR = 3.73; P = .05). Given the shared routes of transmission (through oral-anogenital sexual transmission) between syphilis [27] and HAV, it is possible that acute syphilis is associated with natural booster events by wild-type circulating HAV, which appears not to be uncommon in our relatively young cohort of sexually active MSM [28] . Because there is a Smokers were defined as those who reported to have smoked at least 100 cigarettes in their lifetime. Those who reported never having smoked 100 cigarettes were defined as never smoker.
Abbreviations: aOR, adjusted odds ratio; cART, combination antiretroviral therapy; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus. lack of serological marker of natural HAV infection, unlike that represented by the antibody against the hepatitis B core antigen for hepatitis B infection, we used the arbitrary definition of an otherwise unexplained sustained ≥2-fold rise in anti-HAV IgG following an initial decline. Overall, 26 of the primary responders (11 in the 2-dose group and 15 in the 3-dose group) met the criteria for asymptomatic HAV acquisition, giving rise to a crude incidence rate of 19.6 per 1000 PYFU. On the other hand, acute HCV infection in the follow-up period was a risk factor for loss of protective levels of anti-HAV IgG. Although HCV is also sexually acquired [29] , it is known to suppress the host immune response [30] by infecting immune cells, such as macrophages, B cells, and T cells, as well as interfering with host immune responses through the endogenous interferon system [31] , T cell function [32] , and possibly also dendritic cell function [33] . Hence, it is possible that the immunomodulatory effects of HCV infection predominate and lead to loss of sustained antibody production.
Neither the CD4 cell count nor suppression of HIV replication at time of vaccination was predictive of the development of anti-HAV in our regression analysis in contrast with other published studies [21, 34, 35] . This may be because of the relatively low proportion of patients in our study with very low CD4 cell counts, but notably, only 1 other study, which had 26 patients with long-term follow-up data, has vaccinated patients with >2 vaccine doses [21] . Our data imply that the addition of a 3rd dose of HAV vaccine can ameliorate the degree of immune impairment at baseline, although individuals with more advanced HIV disease may need more time to develop immunity consistent with data from other studies of HAV vaccination among immunocompromised populations [20] .
There are several limitations to this study, and interpretation of our findings should be cautious. First, this was not a randomized controlled trial. Therefore, 3 doses may not outperform 2 in the long run because the proportions of primary responders with persistent seroprotection at 5 years were not statistically different between the 2 dosing groups. However the 3-dose group had significantly lower CD4 cell counts at baseline. Hence, whether subsets of HIV-positive persons with initial low CD4 counts or risk factors such as viral hepatitis would benefit from a 3-dose schedule deserves further study. In addition, any potential benefits of adding a 3rd dose should be weighed against the additional costs incurred. Second, no clinical endpoints to determine vaccine efficacy were studied. Third, our population was comprised entirely of young MSM in an area of low to intermediate HAV endemicity [2] . Hence whether the findings are generalizable to injecting drug users, women or children coinfected with HIV, or individuals residing in areas of higher HAV endemicity remains to be proven.
In conclusion, in this prospective, nonrandomized longitudinal study, the 3-dose group with lower baseline CD4 counts and higher plasma HIV RNA load compared with the 2-dose group maintained higher antibody concentrations but similar seroprotection rates after 5 years. Therefore, 3 doses may overcome the poor responses observed for those with more advanced immunosuppression and render these responses longer lasting because higher titers take longer to serorevert. However, given concurrent cART and subtle immunosuppression, 2 standard doses also achieved highly durable seroprotection (>75%), rendering additional doses or booster vaccinations of questionable relevance for this population.
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